Rite Aid, a once prominent national pharmacy chain, has officially closed all of its locations across the United States. The closure follows a rapid decline, with the company operating 2,451 locations in 2022 before filing for Chapter 11 bankruptcy in October 2023. Despite emerging from bankruptcy briefly, Rite Aid filed again in May 2025, leading to the liquidation of its assets and the complete closure of all stores by September. The company, founded in 1962, faced significant challenges including a heavy debt load and legal issues related to the opioid crisis.
Read More
Qingzhou Wang, principal executive of Amarvel Biotech, has been sentenced to 25 years in prison for trafficking fentanyl precursor chemicals into the United States. Along with marketing manager Yiyi Chen, they were convicted in New York of precursor importation and money laundering. The defendants were part of a group of eight Chinese nationals and four Chinese companies charged in June 2023. This case marked the first time the US charged Chinese companies with trafficking these chemicals directly into the US, rather than shipping them to Mexico.
Read More
States agree to a $7.4 billion settlement with Purdue Pharma, resolving a significant portion of the opioid litigation against the company. This massive settlement, one of the largest in history, aims to address the devastating consequences of the opioid crisis fueled by Purdue Pharma’s marketing of OxyContin. However, the agreement has sparked significant outrage and controversy, with many feeling that it doesn’t adequately reflect the scale of the harm caused and the culpability of the Sackler family, Purdue Pharma’s owners.
The central point of contention revolves around the Sacklers’ apparent ability to retain substantial wealth despite the catastrophic consequences of their actions.… Continue reading
Provisional CDC data reveals a record-setting 27% decrease in U.S. drug overdose deaths in 2024, totaling an estimated 80,000 fatalities. This significant decline, attributed to factors including increased naloxone availability, expanded addiction treatment, and shifting drug use patterns, is the largest single-year drop ever recorded. However, overdose deaths remain higher than pre-pandemic levels and above those of 2018, necessitating continued efforts to sustain progress, as some experts express concerns over potential funding cuts. Despite this success, overdoses continue to be the leading cause of death among young adults.
Read More
Attorney General Pam Bondi attributed the seizure of over 22 million fentanyl pills and 3,400 kilos of fentanyl in President Trump’s first 100 days to saving 258 million lives. This calculation, provided by the DOJ, is based on the amount of fentanyl seized and its purity level, divided by a lethal dose. While the methodology has been questioned, the claim centers on the prevention of potentially fatal overdoses. Further investigation is needed to verify the accuracy and assumptions within the calculation.
Read More
President Trump’s recent Cabinet meeting featured effusive praise for his first 100 days in office, with members employing hyperbolic language to laud his accomplishments. Attorney General Pam Bondi particularly distinguished herself, claiming Trump’s actions saved 258 million lives through fentanyl seizures and exceeding the achievements of all previous presidencies. However, Bondi’s statistics are demonstrably inflated, and the administration’s proposed budget cuts to a Narcan distribution program raise questions about the commitment to combating the opioid crisis. These contradictory actions highlight a disconnect between the administration’s rhetoric and actual policy.
Read More
Attorney General Pam Bondi announced the seizure of over 22 million fentanyl-laced pills during President Trump’s first 100 days, claiming this saved 119 million lives. This assertion was widely criticized online as mathematically implausible, with commentators pointing out that this figure represents roughly one-third of the U.S. population. The significant discrepancy between the claimed number of lives saved and the actual U.S. population fueled widespread ridicule and accusations of innumeracy. Bondi’s statement sparked considerable debate and criticism regarding the accuracy and implications of the administration’s anti-drug claims.
Read More
Despite the success of a federal Narcan distribution program in significantly reducing overdose deaths—a 24% drop in the past year—the proposed Trump administration budget seeks to eliminate its $56 million annual funding. This program has trained over 66,000 individuals and distributed over 282,500 Narcan kits in 2024 alone. This decision, opposed by addiction specialists and public health advocates, risks reversing progress in combating the opioid crisis and jeopardizes vulnerable communities. While HHS Secretary Robert F. Kennedy Jr. acknowledges Narcan’s effectiveness, he advocates for a broader approach focusing on societal and spiritual change.
Read More
Walgreens will pay up to $350 million to settle a Department of Justice lawsuit alleging the company illegally filled millions of opioid and other controlled substance prescriptions between 2012 and 2023. The settlement includes a minimum payment of $300 million, with an additional $50 million contingent on a company sale or merger before 2032. The government accused Walgreens of ignoring red flags indicating invalid prescriptions and pressuring pharmacists to fill them rapidly, ultimately billing federal healthcare programs. Walgreens denies liability but will also implement improved compliance measures with the DEA and HHS.
Read More
Purdue Pharma and the Sackler family have agreed to a $7.4 billion settlement to resolve lawsuits stemming from the opioid crisis caused by OxyContin. The Sacklers will pay up to $6.5 billion and relinquish company ownership, while Purdue will contribute nearly $900 million. This revised settlement, exceeding the previous offer by $500 million, requires court approval but avoids anticipated federal opposition. The funds will compensate victims, address the opioid crisis, and provide treatment resources.
Read More
John Q. Hosedrinker 
Matt Underwood